Adalimumab is used to treat Ankylosing Spondylitis. It is an inflammatory arthritis that affects large joints,spine,lower back.
Crohn Disease is a bowel disease that affects the lining of digestive tract. It’s symptoms are fatigue, anaemia, diarrhea,stomach pain. This disease is also known as ikeitis. Doctor prescribe to treat this disease.
Rheumatoid Arthritis is a chronic condition that affects synovial membrane. Synovial membranes are layer of joints helps in movement. It is more common in women than men.
Ulcerative Colitis is an inflammation of colon and rectum. It mainly affects inner lining of large intestine. Some common symptoms appears are blood in stool,diarrhea, abdominal pain.
Hidradenitis Suppurativa is a chronic disease around apocrine sweat gland. It is mainly seen under armpit, inner thigh, groins.
Plaque Psoriasis is a skin disease. That forming dry,itchy,thick skin. Red patches appear on the skin surface. It mainly occurs on the elbow,legs,palm,nails.
Psoriatic Arthritis is a disease of joint having psoriasis (skin disease). It affects both skin and joint. It is characterized by swollen finger and toes, pitted nails, lower back pains.
It shows onset action after 3-6 injection in most cases. It reduces pain and swelling. It minimizes joint damage. It decrease the risk of disability. Adalimumab prevents muscles weakness and deconditioning
Adalimumab is given subcutaneously. Common dose is 40 mg in every 2 weeks. 80 mg is given in Plaque Psoriasis and uveitis on first day. After 7 days 40 mg every 2 weeks. 160 mg is given in crohn disease and ulcerative colitis on first day. After that 80 mg on 15th days. 40 mg in every weeks started after 19th days.
In Hidradenitis Suppurativa adalimumab dose is 160 mg Sub cutaneous on first day. then doses decreased to 80 mg on 15 days. After 29th days 40 mg doses given in every 2 weeks.
Cancer: Adalimumab increase the risk of cancer. But there is no proper data available for that. So complete care and doctor advise is required.
Neutropenia: In cases of neutropenia adalimumab increase the risk. The patients having neutropenia take s longer time to treat. So avoid adalimumab in that patients for better treatments.
Infection: It also increases the risk of infection more. So there should be proper data of PPD testing, patients selection, vaccination. Before adalimumab provide antibiotic therapy to reduce infection.
Multiple Sclerosis: Adalimumab should not be given for the patients. having Multiple Sclerosis,Optic neuritis,Transverse myelitis,Guillain Barre syndrome.
Lupus like reaction having symptoms like shortness of breath,skin eruption. Other side effect in lungs disease , Vasculitis